Composition for preventing or treating inflammatory disease

Patent metadata

Field	Value
Publication number	US-10709741-B2
Application number	US-201414767331-A
Country	US
Kind code	B2
Filing date	Feb 13, 2014
Priority date	Feb 13, 2013
Publication date	Jul 14, 2020
Grant date	Jul 14, 2020

Abstract

A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease.

First claim

What is claimed:

1. A method of treating an inflammatory disease comprising, administering to a subject in need thereof an effective amount of a composition comprising a culture supernatant, wherein the culture supernatant is obtained by a method comprising
(1) selecting adherent cells from dental pulp cells, and
(2) culturing the adherent cells to at least 70 % confluence,
(3) culturing the cells obtained in step ( 2 ) in serum-free liquid, and
(4) obtaining the supernatant,

wherein the composition does not contain dental pulp stem cells, and
wherein the inflammatory disease is selected from the group consisting of fulminant hepatitis, hepatic cirrhosis, pulmonary fibrosis, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

2. The method according to claim 1 , wherein the composition is administered by an administration method selected from the group consisting of intravenous administration, intra-arterial administration, intraportal administration, intracutaneous administration, subcutaneous administration, intramuscular administration, intraperitoneal administration and intranasal administration.

3. The method according to claim 1 , wherein the inflammatory disease is selected from the group consisting of multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.

4. The method according to claim 1 , wherein the dental pulp cells are human dental pulp cells.

5. The method according to claim 1 , wherein the inflammatory disease is selected from the group consisting of fulminant hepatitis, hepatic cirrhosis, and pulmonary fibrosis.

6. The method according to claim 1 , wherein the inflammatory disease is hepatic cirrhosis.

Assignees

• Univ Nagoya Nat Univ Corp

Inventors

• Yamamoto Akihito
• Ueda Minoru
• Goto Hidemi
• ISHIGAMI Masatoshi
• Matsushita Yoshihiro
• Hasegawa Yoshinori
• Hashimoto Naozumi
• WAKAYAMA Hirotaka

Classifications

• C12N5/0664

  Dental pulp stem cells, Dental follicle stem cells · CPC title

• C12N2502/1364

  Dental pulp stem cells, dental follicle stem cells · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title